Literature DB >> 4020627

Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine.

E R Garrett, V R Chandran.   

Abstract

The 10-fold greater sensitivity of buprenorphine to fluorescence compared with morphine provides excellent detection for HPLC assay of buprenorphine in biological fluids with a 5-ng/mL sensitivity. Buprenorphine yields a stoichiometric final acid degradation product, a fluorescent-detectable, rearranged demethoxy analogue of buprenorphine, which serves as an excellent bioassay internal standard. Buprenorphine solvolysis is specific-acid and specific-base catalyzed. Alkaline hydrolysis produces no fluorescent products. Acid hydrolysis also produces a fluorescent-detectable, transient dehydro intermediate that is also completely transformed to the demethoxy analogue. The rate constants and Arrhenius parameters for these transformations have been determined. Estimated buprenorphine pK'a values are 8.24 and 10 for the ammonium and phenol groups, respectively. The intrinsic aqueous solubility of neutral buprenorphine is 12.7 +/- 1.2 micrograms/mL at 23 degrees C. The red blood cell-plasma water partition coefficients of buprenorphine ranged between 6 and 15. Ultracentrifugation and the red blood cell partition methods led to an estimated 95-98% plasma protein binding. Ultrafiltration and equilibrium dialysis methods were inappropriate because of the high membrane binding of neutral buprenorphine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4020627     DOI: 10.1002/jps.2600740505

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs.

Authors:  B KuKanich; P Allen
Journal:  J Vet Pharmacol Ther       Date:  2014-03-29       Impact factor: 1.786

Review 2.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 3.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis).

Authors:  Elizabeth A Nunamaker; Lisa C Halliday; David E Moody; Wenfang B Fang; Matthew Lindeblad; Jeffrey D Fortman
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-01       Impact factor: 1.232

5.  Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta).

Authors:  K R Kelly; B H Pypendop; K L Christe
Journal:  J Vet Pharmacol Ther       Date:  2014-03-25       Impact factor: 1.786

6.  Prediction of aqueous intrinsic solubility of druglike molecules using Random Forest regression trained with Wiki-pS0 database.

Authors:  Alex Avdeef
Journal:  ADMET DMPK       Date:  2020-03-04

7.  Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review.

Authors:  S Deandrea; O Corli; I Moschetti; G Apolone
Journal:  Ther Clin Risk Manag       Date:  2009-09-15       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.